六味地黄丸联合康复新液治疗复发性阿弗他溃疡临床研究  

Clinical Study on Liuwei Dihuang Pills Combined with Kangfuxin Liquid for Recurrent Aphthous Ulcer

作　　者：杨舒 徐勤业[1] YANG Shu;XU Qinye(Department of Stomatology'Yiwu Central Hospital,Yiwu Zhejiang 321000,China)

机构地区：[1]义乌市中心医院口腔科,浙江义乌321000

出　　处：《新中医》2023年第16期61-64,共4页New Chinese Medicine

摘　　要：目的:观察六味地黄丸联合康复新液治疗复发性阿弗他溃疡的临床疗效。方法:按随机数字表法将170例复发性阿弗他溃疡患者分为对照组和治疗组各85例。对照组采取康复新液治疗,治疗组在对照组基础上加用六味地黄丸治疗。2组均连续治疗15 d,比较2组治疗前后症状体征积分、视觉模拟评分法(VAS)评分、T淋巴细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)水平变化,以及临床疗效和不良反应发生率。结果:治疗组总有效率为96.47%,对照组为87.06%,2组比较,差异有统计学意义(P<0.05)。治疗前,2组症状体征积分、VAS评分比较,差异均无统计学意义(P>0.05);治疗后,2组症状体征积分、VAS评分均较治疗前下降(P<0.05),且治疗组症状体征积分、VAS评分均低于对照组(P<0.05)。治疗前,2组T淋巴细胞亚群CD3+、CD4+、CD8+、CD4+/CD8+水平比较,差异均无统计学意义(P>0.05)。治疗后,2组CD8+水平较治疗前降低(P<0.05),CD3+、CD4+、CD4+/CD8+水平较治疗前升高(P<0.05);且治疗组CD8+水平低于对照组(P<0.05),CD3+、CD4+、CD4+/CD8+水平高于对照组(P<0.05)。治疗组不良反应发生率为3.53%,对照组为8.24%,2组比较,差异无统计学意义(P>0.05)。结论:六味地黄丸联合康复新液治疗复发性阿弗他溃疡,能显著提高临床疗效,减轻疼痛,改善患者的免疫功能及中医证候。Objective:To observe the clinical effect of Liuwei Dihuang Pills combined with Kangfuxin Liquid for recurrent aphthous ulcer.Methods:A total of 170 cases of recurrent aphthous ulcer patients were divided into the control group and the treatment group according to the random number table method,with 85 cases in each group.The control group was treated with Kangfuxin Liquid,and the treatment group was additionally treated with Liuwei Dihuang Pills based on the treatment of the control group.Both groups were treated for 15 days.The changes symptom and signs scores,pain scores,and levels of CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)of T lymphocyte subsets before and after treatment,the clinical effects,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate was 96.47%in the treatment group and 87.06%in the control group,the difference being significant(P<0.05).Before treatment,there was no significant difference being found in the comparison of symptoms and signs scores and Visual Analogue Scale(VAS)scores between the two groups(P>0.05);after treatment,symptoms and signs scores and VAS scores in the two groups were decreased when compared with those before treatment(P<0.05),and the symptoms and signs score and VAS score in the treatment group were lower than those in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of the levels of CD3^(+),CD4^(+),CD8^(+),and CD4^(+)/CD8^(+)of T lymphocyte subsets between the two groups(P>0.05).After treatment,CD8^(+)levels in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)were increased when compared with those before treatment(P<0.05);CD8^(+)level in the treatment group was lower than that in the control group(P<0.05),and the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)were higher than those in the control group(P<0.05).The incidence of adverse reactions was 3.53%in the treatment group an

关 键 词：复发性阿弗他溃疡 六味地黄丸 康复新液 T淋巴细胞亚群 

分 类 号：R781.5[医药卫生—口腔医学]